Lantheus Medical Imaging will showcase the potential of its PyL (F-18 DCFPyL) radiopharmaceutical at the virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 annual meeting, July 11-14.
PyL is an investigational prostate-specific membrane antigen-targeted small-molecule PET radiopharmaceutical that aims to visualize prostate cancer. Data from company-sponsored studies of PyL will be presented on July 11 in the Science Pavilion at SNMMI 2020.
The information that will be presented evaluates the diagnostic performance and clinical impact of PyL in patients with biochemical recurrence of prostate cancer. Another abstract focuses on a digital solution Latheus is developing with PyL in the hopes of supporting prostate cancer staging with the use of the automated miPSMA index of the PET/CT PyL-prostate specific membrane antigen (PSMA) images.
